JP2018524320A5 - - Google Patents

Download PDF

Info

Publication number
JP2018524320A5
JP2018524320A5 JP2017566028A JP2017566028A JP2018524320A5 JP 2018524320 A5 JP2018524320 A5 JP 2018524320A5 JP 2017566028 A JP2017566028 A JP 2017566028A JP 2017566028 A JP2017566028 A JP 2017566028A JP 2018524320 A5 JP2018524320 A5 JP 2018524320A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutical composition
crystal
cyclic amide
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017566028A
Other languages
English (en)
Japanese (ja)
Other versions
JP6768716B2 (ja
JP2018524320A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/038340 external-priority patent/WO2016205785A1/en
Publication of JP2018524320A publication Critical patent/JP2018524320A/ja
Publication of JP2018524320A5 publication Critical patent/JP2018524320A5/ja
Application granted granted Critical
Publication of JP6768716B2 publication Critical patent/JP6768716B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017566028A 2015-06-19 2016-06-20 カルボプラチンベースの共結晶の医薬組成物及びその用途 Expired - Fee Related JP6768716B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562182142P 2015-06-19 2015-06-19
US62/182,142 2015-06-19
PCT/US2016/038340 WO2016205785A1 (en) 2015-06-19 2016-06-20 Pharmaceutical composition of carboplatin based co-crystals and use thereof

Publications (3)

Publication Number Publication Date
JP2018524320A JP2018524320A (ja) 2018-08-30
JP2018524320A5 true JP2018524320A5 (enExample) 2019-07-11
JP6768716B2 JP6768716B2 (ja) 2020-10-14

Family

ID=57546414

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017566028A Expired - Fee Related JP6768716B2 (ja) 2015-06-19 2016-06-20 カルボプラチンベースの共結晶の医薬組成物及びその用途

Country Status (9)

Country Link
US (1) US10421770B2 (enExample)
EP (1) EP3297636B1 (enExample)
JP (1) JP6768716B2 (enExample)
KR (1) KR20180018800A (enExample)
CN (1) CN107847508B (enExample)
AU (1) AU2016279099B2 (enExample)
BR (1) BR112017027285A2 (enExample)
CA (1) CA2988992A1 (enExample)
WO (1) WO2016205785A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135877B (zh) * 2015-05-18 2021-04-13 新纳特产品公司 药物共晶及其用途
JP6768716B2 (ja) 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
BR112017027277A2 (pt) 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
CN107847521A (zh) 2015-06-25 2018-03-27 新纳特产品公司 药物共晶组合物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922689A (en) 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US6297245B1 (en) 1998-08-04 2001-10-02 Unitech Pharmaceuticals Cisplatin and folic acid administered to treat breast cancer
KR100317473B1 (ko) 1999-05-11 2001-12-22 이계호 신규의 백금(iv)착제 및 그 제조방법
CN1121380C (zh) 2000-03-03 2003-09-17 北京兴大豪斯科技有限公司 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
WO2003045962A1 (fr) * 2001-11-30 2003-06-05 Jingzun Wang Derives de carboplatine supramoleculaires, leur preparation, compositions pharmaceutiques les contenant comme ingredient actif et utilisations de ces compositions
WO2004078163A2 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
BR0313593A (pt) 2002-08-19 2005-07-12 Pfizer Prod Inc Terapia de combinação para doenças hiperproliferativas
WO2004099224A1 (de) 2003-05-05 2004-11-18 Universität Regensburg Carboplatin-artige platin (ii)- komplexe
ATE453653T1 (de) 2003-08-13 2010-01-15 Univ South Florida Platinkomplexe zur behandlung von tumoren
CA2548281C (en) * 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
MX2007008810A (es) * 2005-01-21 2007-11-21 Astex Therapeutics Ltd Compuestos farmaceuticos.
CN100500219C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种含铂类化合物的抗实体肿瘤药物组合物
RU2008135369A (ru) 2006-01-30 2010-03-10 Платко Текнолоджис (Проприэтэри) Лимитед (Za) Получение комплексов платины(ii)
PL2049109T3 (pl) 2006-08-02 2016-05-31 Sunesis Pharmaceuticals Inc Skojarzone zastosowanie kwasu (+)-1,4-dihydro-7-[(3s,4s)-3-metoksy-4-(metyloamino)-1-pirolidynylo]-4-okso-1-(2-tiazolilo)-1,8-naftyrydyno-3-karboksylowego i cytarabiny (Ara-C) do leczenia białaczki
BRPI0808526A2 (pt) * 2007-03-02 2014-08-19 Novartis Ag Formas sólidas de um inibidor de raf cinase
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
KR100957125B1 (ko) * 2008-01-14 2010-05-11 한국과학기술원 생체 고분자와 난용성 물질의 접합체 및 그의 제조방법
AU2009290365B2 (en) 2008-09-15 2014-08-14 Kasina Laila Innova Pharmaceuticals Private Limited Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
CZ302618B6 (cs) 2009-09-10 2011-08-03 Univerzita Palackého Cyklobutan-1,1-dikarboxylátokomplexy platiny s deriváty N6-benzyladeninu, zpusoby jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
US20110287110A1 (en) 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
JP5179628B2 (ja) 2011-07-15 2013-04-10 ユニーテック株式会社 4価白金錯体及びそれを含む医薬組成物
US9220705B2 (en) 2013-03-07 2015-12-29 James David Hoeschele Method of treating colorectal cancer
SI3424920T1 (sl) 2013-10-17 2020-08-31 Vertex Pharmaceuticals Incorporated Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk
CN111638234B (zh) * 2014-08-13 2024-09-03 北京默加农生物技术发展有限公司 一种以双环铂为有效成分的药物的检测方法
CN104127402B (zh) 2014-08-15 2019-08-30 北京默加农生物技术发展有限公司 双环铂在制备抗病毒药物和抗菌药物中的应用
CN104693245A (zh) * 2015-03-13 2015-06-10 卓越同达医药科技开发(苏州)有限公司 超分子抗癌药物双环铂的制备方法
WO2016164040A1 (en) 2015-04-10 2016-10-13 Syn-Nat Products Enterprise LLC Process for the preparation of dicycloplatin
US20180085377A1 (en) 2015-04-22 2018-03-29 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
CN108135877B (zh) 2015-05-18 2021-04-13 新纳特产品公司 药物共晶及其用途
JP6768716B2 (ja) 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
BR112017027277A2 (pt) 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
CN107847521A (zh) 2015-06-25 2018-03-27 新纳特产品公司 药物共晶组合物及其用途

Similar Documents

Publication Publication Date Title
JP2018520147A5 (enExample)
ES2958828T3 (es) Derivados de piridina y su uso para tratar una infección por VIH
JP6606692B2 (ja) (2R,5S,13AR)−8−ヒドロキシ−7,9−ジオキソ−N−(2,4,6−トリフルオロベンジル)−2,3,4,5,7,9,13,13A−オクタヒドロ−2,5−メタノピリド[1’,2’:4,5]ピラジノ[2,1−b][1,3]オキサゼピン−10−カルボキサミドの結晶形
JP2013056886A5 (enExample)
AU2018203175B2 (en) Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
JP2016121196A5 (enExample)
JP2020532532A5 (enExample)
JP2018524320A5 (enExample)
JP2016537346A5 (enExample)
JP2020503010A5 (enExample)
JP2014521688A5 (enExample)
JP2018516238A5 (enExample)
JP2014503525A5 (enExample)
JP2018521969A5 (enExample)
JP2020511943A5 (enExample)
JP2018504378A5 (enExample)
JP2017536344A5 (enExample)
BR112013002375B1 (pt) Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto
JP2018504379A5 (enExample)
JP2018522866A5 (enExample)
JP2016006096A5 (enExample)
JP2016508150A (ja) ウイルス感染症を処置するための治療用化合物
JP2015517555A5 (enExample)
JP2020507589A5 (enExample)
JP2018515563A5 (enExample)